Clinical research
Genentech announced that the FDA has green-lit the Venclexta classification and azicitidine combination as a Breakthrough Therapy Drug.
The lawsuit alleges that Ocugen made “materially false and misleading statements” about its operations and compliance policies.
The drug is a nucleoside reverse transcriptase translocation inhibitor, with the results presented at the virtual 11th International AIDS Society Conference on HIV Science.
The recent survival results of Masitinib will help (ALS) patients to live longer. AB Science has successfully established the sweet spot for masitinib in ALS.
Genentech’s Hemlibra showed no new safety signals and continued to deliver consistent bleeding control in the final analysis of a long-term, late-stage hemophilia A study.
The firm would be moving forward to Phase III for the treatment of hypertrophic cardiomyopathy, which is expected to commence before the end of 2021.
The CDC Advisory Committee on Immunization Practices is planning a meeting in October to recommend the vaccine’s use in adults.
Boston-based Alexion Pharmaceuticals announced positive topline data from its Phase III trial of Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis.
It was a moderately busy mid-summer week for clinical trial news. Here’s a look.
The randomized, multi-center study called CheckMate -651 evaluates Opdivo 3 mg/kg every two weeks in combination with Yervoy 1mg/kg every six weeks.
PRESS RELEASES